New blood test could end Trial-and-Error for arthritis drugs

NCT ID NCT07150000

Recruiting now Diagnosis Sponsor: University of Bonn Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. If successful, this could replace the current trial-and-error approach, helping patients find effective treatment faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ex vivo diagnostic assay using patient blood cells
What this could lead to: If successful, this could give doctors a simple blood test to pick the right drug for each patient, speeding up relief and reducing side effects.
What could go wrong: This is an early-stage study (120 participants) testing a lab assay, not a treatment. The test may not accurately predict real-world responses or work for all rheumatic diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS (AAV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis anti-neutrophil cytoplasmic antibody-associated vasculitis Arthritis, Gouty autoinflammatory syndrome connective tissue disorder Giant Cell Arteritis gout granulomatosis with polyangiitis idiopathic inflammatory myopathy myositis disease polymyalgia rheumatica psoriatic arthritis rheumatic disorder rheumatoid arthritis systemic lupus erythematosus systemic sclerosis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS (AAV) AUTOINFLAMMATORY DISEASE AXIAL SPONDYLARTHRITIS (AXSPA) CONNECTIVE TISSUE DISEASE (CTD) GIANT CELL ARTERITIS (GCA) GOUT ARTHRITIS IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) POLYMYALGIA RHEUMATICA (PMR) PSORIATIC ARTHRITIS (PSA) RHEUMATIC DISEASES RHEUMATOID ARTHRITIS (RA) SYSTEMIC LUPUS ERTHEMATOSUS (SLE) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University Hospital, Bonn
RECRUITING

Bonn, North Rhine-Westphalia, 53127, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.